ACHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Acadia Healthcare Company Inc (ACHC) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are some positive technical indicators and analyst upgrades, the company's poor financial performance, hedge fund selling, and lack of significant positive catalysts make it prudent to hold off on buying at this time.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram (0.0667), and RSI_6 at 70.993, which is neutral. Key resistance levels are at R1: 27.599 and R2: 28.869, while support levels are at S1: 23.489 and S2: 22.219. The stock is in a short-term uptrend but lacks strong momentum.
Analyst upgrades with raised price targets, including RBC Capital's focus on operational improvements and UBS's Buy rating with a $27 target. Bullish moving averages and a slight post-market price increase of 0.22%.
Insider trading trends are neutral, and there is no recent congress trading data. Lack of significant news or event-driven catalysts.
In Q4 2025, revenue increased by 6.10% YoY to $821.46M. However, net income dropped drastically to -$1.18B (-3710.36% YoY), and EPS fell to -13.02 (-3820.00% YoY). Gross margin remained flat at 100%. The financials indicate severe profitability issues despite revenue growth.
Analysts have mixed views. UBS, RBC Capital, and Deutsche Bank maintain Buy ratings with raised price targets ($27, $28, and $26, respectively). However, Jefferies downgraded the stock to Hold with a $15 target, citing operational and macro headwinds. Cantor Fitzgerald and Mizuho remain Neutral, highlighting concerns about Medicaid pressure and execution risks.
